Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
NCT03191799Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2017
- Primary completion
- Nov 2020
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Roche. Primary endpoints: Overall Summary of the Number of Participants With Adverse Events up to 2 years, Adverse Events Rates Per 100 Patient-Years up to 2 years and 7 more. Started Sep 2017; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03191799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191799.